ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Impel Neuropharma Announces First Patient Dosed In INP104 Trial
americanpharmaceuticalreview
August 27, 2018Impel NeuroPharma announced the first patient has been dosed in the company's Phase 3, open-label safety and tolerability study evaluating long-term, intermittent use of INP104 for the treatment of migraine headache.
Pharma Sources Insight January 2025
